Diabetes Care Drugs & Devices Market Attracts Investment in Smart Insulin Pens & Apps | F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc

"Global Diabetes Care Drugs & Devices Market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033." As per DataM intelligence research report

Diabetes Care Drugs & Devices Market growth opportunities(2025-2031):

The diabetes care drugs and devices market is set to grow steadily, driven by the increasing global prevalence of Type 1 and Type 2 diabetes, lifestyle-related risk factors, and expanding access to diagnostic and treatment options. Digital health integration, such as app-connected glucose monitors and smart insulin delivery systems, is reshaping diabetes self-management. Personalized medicine and combination therapies are gaining ground as pharmaceutical innovation focuses on improving glycemic control and reducing comorbid risks. Meanwhile, public health initiatives and value-based healthcare models are pushing for early diagnosis and better long-term care adherence. Emerging economies present major untapped potential due to rising disease burden and healthcare infrastructure upgrades.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/diabetes-care-drugs-and-devices-market?sp

Diabetes Care Drugs & Devices Market: Recent Industry Developments

✅ In July 2025, Dexcom launched its G8 Continuous Glucose Monitor (CGM) with real-time insulin dosing support.It features improved accuracy, longer wear (15 days), and full smartwatch integration.The device is already seeing rapid adoption across major U.S. endocrinology clinics.

✅ In June 2025, Eli Lilly invested $120 million to expand its smart insulin pen platform in the U.S. market.The pen syncs with CGMs and alerts users for missed doses via mobile apps.This move enhances Lilly's footprint in tech-enabled diabetes drug delivery.

✅ In May 2025, Abbott received FDA approval for its FreeStyle Libre 4 system.
It offers pain-free glucose readings every minute with AI-based trend forecasting.The U.S. launch includes expanded access through Medicare and private insurers.

✅ In April 2025, Tandem Diabetes Care introduced T-slim X3, its next-gen insulin pump.It features a faster bolus delivery, smaller form factor, and advanced touchscreen.U.S. preorders exceeded 50,000 units in the first month of announcement.

✅ In March 2025, Vertex Pharmaceuticals started Phase 2 trials of its VX-880 islet cell therapy.This investigational drug targets Type 1 diabetes by restoring natural insulin production.The trial was fast-tracked by the FDA and shows early signs of durable efficacy.

Diabetes Care Drugs & Devices Market: Drivers

The Diabetes Care Drugs & Devices market is primarily driven by the alarming rise in global diabetes cases, fueled by sedentary lifestyles, unhealthy diets, and aging populations. Continuous advancements in insulin delivery systems-such as smart pens, wearable pumps, and patches-are improving treatment precision and patient compliance. Breakthroughs in continuous glucose monitoring (CGM) technology are enabling real-time tracking and better glycemic control. Growing patient preference for minimally invasive and automated management tools is further boosting device adoption. Increased awareness and screening initiatives are also encouraging early diagnosis and proactive diabetes management.

Supportive government policies and expanding insurance coverage, especially for CGM and insulin devices, are reducing out-of-pocket costs and broadening access. Pharmaceutical innovation is also strong, with newer drug classes like GLP-1 receptor agonists and SGLT-2 inhibitors offering added cardiovascular and renal benefits. The rise of digital health platforms and AI-powered tools is enabling personalized diabetes care and remote monitoring. Emerging economies are witnessing rapid market growth due to urbanization, healthcare infrastructure upgrades, and rising disposable incomes. Strategic collaborations between pharma and medtech firms are accelerating the launch of integrated, user-friendly solutions.

Diabetes Care Drugs & Devices Market: Technological Advancements

✦ Continuous Glucose Monitoring (CGM) systems now feature real-time data sharing, predictive alerts, and app-based trend analysis, enhancing self-monitoring and care precision.
✦ Smart insulin pens and patch pumps offer accurate dosing, connectivity, and ease of use, improving compliance and patient experience.
✦ Closed-loop insulin delivery systems (artificial pancreas) integrate CGM with automated pumps, delivering dynamic insulin responses based on real-time glucose readings.
✦ Oral semaglutide and dual GIP/GLP-1 receptor agonists represent significant breakthroughs in drug therapy by offering cardiovascular benefits and weight management support.
✦ Tele-diabetes platforms and digital therapeutics enable remote consultation, personalized coaching, and AI-guided dosing recommendations for enhanced disease management.

Strategic Players Driving the Diabetes Care Drugs & Devices Market Forward:

F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Merck & Co., Inc., Novo Nordisk A/S., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Insulet Corporation and among others.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diabetes-care-drugs-and-devices-market?sp

Research Methodology:

The global Diabetes Care Drugs & Devices Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Diabetes Care Drugs & Devices Market:

➥By Product Type: Diabetes Devices, Diabetes Drugs
➥By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes
➥By End-User: Hospitals, Specialty Clinics, Homecare Settings, Diagnostic Centers, Others

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetes-care-drugs-and-devices-market?sp

Regional Analysis for Diabetes Care Drugs & Devices Market:

North America leads the global market, driven by high diabetes prevalence, strong reimbursement systems, and early adoption of digital health solutions. Europe follows closely, supported by well-structured healthcare systems and increasing preference for minimally invasive and tech-enabled diabetes care. Asia-Pacific is the fastest-growing region, propelled by rising urbanization, dietary shifts, genetic predisposition, and healthcare infrastructure investments in countries like India and China.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.